Journal of Yeungnam Medical Science

Original Articles

Chemokines Expression in Children with a Non-productive Cough.: Young Hwan Lee, Hee Sun Kim; Yeungnam Univ J Med. 2007;24(2):129-136. Published online December 31, 2007; DOI: https://doi.org/10.12701/yujm.2007.24.2.129

Abstract PDF: PURPOSE: To evaluate the chemokine expression in children with a non-productive cough. MATERIALS AND METHODS: Six children with a non-productive cough who visited Yeungnam University Hospital were evaluated for the mRNA expression of interferon-gamma-inducible protein 10(IP-10), macrophage cationic protein 1 and 3 (MCP-1, 3), interleukin (IL)-8, regulated upon activation in normal T cells expressed and secreted (RANTES), eotaxin and growth-related oncogene-alpha (Gro-alpha) using the reverse transcription polymerase chain reaction. RESULTS: The chemokines IP-10 and MCP-3 were expressed in all samples. The chemokine RANTES was expressed in five cases, and IL-8 was expressed in three among them. However, eotaxin, Gro-alpha and MCP-1 were not expressed at all. The expression of chemokine MCP-3, RANTES and IL-8 were suppressed after the resolution of coughing in just one available case. CONCLUSION: The chemokines MCP-3, RANTES and IL-8 may contribute to airway inflammation in children with a non-productive cough, whereas IP-10 is of secondary importance in this condition.

Antihypertensive effect and safety of imidapril on the patient with essential hypertension.: Gue Ru Hong, Jun Ho Bae, Dae Jin Jun, Jong Seon Park, Dong Gu Shin, Young Jo Kim, Bong Sup Sim; Yeungnam Univ J Med. 1999;16(1):69-75. Published online June 30, 1999; DOI: https://doi.org/10.12701/yujm.1999.16.1.69

Abstract PDF: Imidapril(Tanatril(R)), a newly developed ACE inhibitor, has been used to treat hypertension and congestive heart failure. This study was designed to assess the antihypertensive effect and safety of Imidapril(Tanatril(R)) in patient with essential hypertension. 5-10mg of imidapril(Tanatril(R)) was administered once day in 30 patients with essential hypertension and followed up to 8 weeks. We tested the drug's effectiveness, safety, and the incidence of imidapril induced dry coughs. After 8 weeks of treatment with Imidapril, 76.2%(16/21) of patient showed lowered blood pressure and 47.6% showed normal blood pressure. The overall incidence of adverse effects was 33.3%(7/21). and among these adverse effects. dry cough was shown in only 9.5%. Thus, concluded that imidapril(Tanatril(R)) is as safe and effective as other ACE inhibitors. especially with imidapril showing very little incidence of dry cough compared to other ACE inhibitors.

Search